Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.72 -1.84%

-$0.18 today

Market cap
$1.27B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.34M

Average 4.58M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$244.63M

FY 2025 · Annual

Investing Cash Flow

-$78.27M

FY 2025 · Annual

Financing Cash Flow

$27.74M

FY 2025 · Annual

-89.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
Deferred Income Tax00000
Stock-Based Compensation183.63M130.3M85.36M48.15M36.02M
Change in Working Capital1.73B(361.15M)(376.84M)48.48M(887.71M)
Accounts Receivables(192.27M)249.17M(274.44M)354.09M61.04M
Inventory(600.33M)(477.8M)(74.46M)12.91M(3.24M)
Accounts Payables600.33M913.4M(378.81M)(385.63M)(322.57M)
Other Working Capital1.93B(1.05B)350.87M67.11M(622.94M)
Other Non-Cash Items136.79M443.8M81.35M(44.89M)139.14M
Operating Cash Flow322.95M(415.94M)(713.97M)(87.26M)(244.64M)
Capital Expenditures(57.49M)(92.99M)(58.81M)(13.06M)(5.56M)
Acquisitions (Net)57.49M00192.64M0
Purchases of Investments(2.17M)00(825.59M)(445.27M)
Sales of Investments159.81M00443.55M353.74M
Other Investing Activities(57.49M)00018.83M
Investing Cash Flow100.15M(92.99M)(58.81M)(204.04M)(78.27M)
Debt Repayment(127.91M)81.66M(352.35M)(3.99M)32.53M
Common Stock Issued564.86M249.23M360.24M263.27M0
Common Stock Repurchased0000(4.8M)
Dividends Paid00000
Other Financing Activities24.76M(5.9M)(3.59M)1.31M0
Financing Cash Flow461.71M324.99M4.47M260.58M27.74M
Effect of Forex Changes(5.29M)4.52M3.27M(7.8M)5.93M
Net Change in Cash879.52M(179.41M)(765.04M)(38.52M)(289.24M)
Free Cash Flow265.46M(508.92M)(772.77M)(100.32M)(250.2M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$440.3M
+ D&A$27.6M
+ Stock-Based Comp$36.0M
+ Deferred Tax$0
- Working Capital-$887.7M
+ Other Non-Cash$139.1M
= Operating Cash Flow-$244.6M
- Capex-$5.6M
= Free Cash Flow-$250.2M

Analysis

FY2025 free cash flow is -$250.2M. FCF conversion is -56.8% of net income. Operating cash flow was -$244.6M, with capex of -$5.6M. The largest bridge item is Working Capital at -$887.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportOct 29, 2026
SC 13D/ASC 13D/A filingOct 16, 2026

Does NVAX generate free cash flow?

Novavax, Inc. (NVAX) generated -$250.19M of free cash flow in fiscal 2025.

How much operating cash flow does NVAX produce?

Operating cash flow was -$244.63M, before capital expenditures of $5.56M.